{"id":"NCT01422434","sponsor":"LEO Pharma","briefTitle":"LEO 90105 Ointment in Japanese Subjects With Psoriasis","officialTitle":"Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-08-24","resultsPosted":"2014-03-11","lastUpdate":"2025-03-12"},"enrollment":676,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"LEO 90105 = calcipotriol + betamethasone dipropionate","otherNames":["LEO 90105 = Dovobet/Daivobet/Taclonex"]},{"type":"DRUG","name":"Dovonex® = calcipotriol","otherNames":[]},{"type":"DRUG","name":"Rinderon® - DP = betamethasone dipropionate","otherNames":[]}],"arms":[{"label":"LEO 90105 ointment","type":"ACTIVE_COMPARATOR"},{"label":"Dovonex® ointment","type":"ACTIVE_COMPARATOR"},{"label":"Rinderon® - DP ointment","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.","primaryOutcome":{"measure":"Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)","timeFrame":"Baseline to Week 4","effectByArm":[{"arm":"Dovonex® Ointment","deltaMin":-50.5,"sd":32.1},{"arm":"LEO 90105 Ointment","deltaMin":-64.3,"sd":24.7},{"arm":"Rinderon® - DP Ointment","deltaMin":-53.6,"sd":26.4}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":25},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.leopharmatrials.com/en"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":226},"commonTop":["Nasopharyngitis","Psoriasis"]}}